23rd May 2014 09:36
LONDON (Alliance News) - Healthcare company BTG PLC Friday said that the US Food and Drug Administration had cleared the use of its EkoSonic endovascular system for the treatment of pulmonary embolism.
In a statement, the company said the clearance for the use of the system for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism was an expanded indication for the system.
Pulmonary embolism is the sudden blockage of an artery in the lung. It most commonly results from deep vein thrombosis, when a blood clot in the deep veins of the legs or pelvis breaks off and migrates to the lung.
The EkoSonic system is made by EKOS Corp, which BTG bought in July last year.
BTG shares were up 4.2% at 570 pence Friday morning, one of the biggest gains on the FTSE 250.
Last week, BTG reported higher pretax profit for its last financial year, as higher revenue and reduced impairment charges more than offset increased research and development spending and the costs of launching varicose vein treatment Varithena.
The company also gave a bullish outlook, saying it expects to further expand the business at the same time as delivering profitable growth.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
BTG